Physician profile
John E Peterson
NPI 1295728236
$6,442.18
in general payments reported to CMS, 2019-2025
50 companies · $411 in 2025
The $411 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,363 · 2020: $841 · 2021: $1,182 · 2022: $1,172 · 2023: $965 · 2024: $509 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,884.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,884.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $757.18 | 2019-2023 | Synjardy, Jardiance, Tradjenta |
| Astrazeneca Pharmaceuticals Lp | $752.61 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $750.48 | 2021-2025 | |
| Novo Nordisk INC | $673.44 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $588.70 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $529.79 | 2019-2025 | |
| Amgen INC. | $193.92 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $185.17 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $139.42 | 2020-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbott Laboratories | $115.93 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Kowa Pharmaceuticals America, INC. | $109.06 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $106.82 | 2021-2024 | Ajovy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $101.01 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $99.53 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $94.07 | 2019-2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Peterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.